Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18888371 | SOLID PSILOCIN SALTS | September 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18663460 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | May 2024 | November 2024 | Allow | 6 | 1 | 0 | No | No |
| 18594323 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | March 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18431308 | POTENTIATION OF HELMINTH TREATMENT | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18403360 | STERICALLY STABILIZED CARRIER COMPOSITIONS FOR TREATING A MAMMAL | January 2024 | November 2024 | Allow | 11 | 0 | 1 | No | No |
| 18402538 | 6-[4,4-BIS(4-BROMOPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUND | January 2024 | October 2024 | Allow | 10 | 3 | 0 | No | No |
| 18398480 | 4-[4,4-BIS(4-BROMOPHENYL)-5-OXO-2-THIOXOIMIDAZOLIDIN-1-YL]BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | December 2023 | October 2024 | Allow | 10 | 3 | 0 | No | No |
| 18515734 | TREATING PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | November 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18495012 | NICOTINE FORMULATION | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18481787 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | October 2023 | November 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18376339 | INJECTABLE IBUPROFEN FORMULATION | October 2023 | May 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18474108 | IMMUNOREGULATORY MICROPARTICLES FOR MODULATING INFLAMMATORY ARTHRITIDES | September 2023 | September 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18457567 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | August 2023 | November 2024 | Allow | 15 | 1 | 0 | No | No |
| 18362028 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | July 2023 | September 2024 | Allow | 13 | 1 | 0 | No | No |
| 18349221 | ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION | July 2023 | April 2025 | Allow | 21 | 3 | 0 | No | No |
| 18325919 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS | May 2023 | August 2024 | Allow | 14 | 2 | 0 | No | No |
| 18302713 | PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME | April 2023 | December 2024 | Abandon | 20 | 2 | 0 | No | No |
| 18095877 | COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | January 2023 | February 2025 | Abandon | 25 | 2 | 0 | Yes | No |
| 18093774 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | January 2023 | October 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 18059806 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | November 2022 | July 2024 | Allow | 20 | 2 | 0 | No | No |
| 17989298 | COLLAGEN-BASED DEVICE HAVING ANTIFUNGAL PROPERTIES | November 2022 | March 2025 | Abandon | 28 | 2 | 0 | No | Yes |
| 18049508 | ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOF | October 2022 | March 2025 | Allow | 29 | 4 | 0 | Yes | No |
| 17950802 | METHODS OF TREATING OCULAR INFLAMMATORY DISEASES | September 2022 | November 2024 | Allow | 26 | 3 | 0 | Yes | No |
| 17745126 | GPR40 AGONISTS | May 2022 | December 2024 | Allow | 31 | 5 | 1 | No | No |
| 17713384 | Osteogenic agents and uses thereof | April 2022 | April 2025 | Allow | 36 | 3 | 1 | No | No |
| 17683197 | Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections | February 2022 | August 2024 | Allow | 30 | 2 | 0 | No | No |
| 17579271 | NEXT GENERATION REMDESIVIR ANTIVIRALS | January 2022 | June 2025 | Allow | 41 | 4 | 1 | No | No |
| 17513383 | PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOF | October 2021 | February 2023 | Abandon | 16 | 3 | 0 | No | Yes |
| 17605828 | DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOR | October 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17593877 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | September 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17598500 | METHOD OF PROTECTING FIELD CORN FROM DAMAGE BY A PLANT PATHOGEN | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17438841 | SPECIFICALLY SUBSTITUTED 3-(2-HALOGEN-6-ALKYL-4-PROPINYLPHENYL)-3-PYRROLIN-2-ONES AND TO THE USE THEREOF AS HERBICIDES | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17438452 | COMBINATION DRUG TREATMENT FOR HUMAN CYTOMEGALOVIRUS | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17437236 | INHIBITION OF ADENOVIRUS WITH FILOCICLOVIR | September 2021 | April 2025 | Allow | 43 | 2 | 0 | No | No |
| 17431470 | MULTIPHASIC CONTRACEPTIVE AND/OR HORMONE REPLACEMENT THERAPY | August 2021 | May 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17428029 | TREATMENT AND PREVENTION OF INTESTINAL INFLAMMATORY DISEASES WITH A BILE ACID DERIVATIVE | August 2021 | January 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17381857 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | July 2021 | June 2024 | Abandon | 35 | 3 | 1 | No | No |
| 17419664 | 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | June 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17331366 | METHODS OF TREATING THROMBOSIS | May 2021 | March 2025 | Allow | 45 | 4 | 1 | Yes | No |
| 17289816 | TARGETING THE TRANSCRIPTION FACTOR NF-KB WITH HARMINE | April 2021 | May 2025 | Abandon | 49 | 4 | 1 | No | No |
| 17099531 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS | November 2020 | November 2024 | Abandon | 48 | 4 | 0 | Yes | No |
| 17014954 | CANNABINOID FORMULATIONS AND METHODS INCLUDING THE ANTIOXIDANT C60 | September 2020 | November 2024 | Abandon | 50 | 4 | 0 | No | No |
| 16767886 | COMPOSITIONS AND METHODS FOR CHARACTERIZING CANCER | May 2020 | November 2024 | Abandon | 54 | 4 | 0 | Yes | No |
| 16624549 | Stratification Of Acute Myeloid Leukaemia Patients For Sensitivity To Kinase Pathway Inhibitor Therapy | December 2019 | December 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16419892 | Method for activating AMPK and the use of Adenine | May 2019 | May 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 16277871 | COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | February 2019 | February 2020 | Allow | 12 | 1 | 0 | No | No |
| 16309733 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN | December 2018 | January 2025 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 16065441 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | June 2018 | September 2024 | Allow | 60 | 7 | 0 | Yes | Yes |
| 15732352 | Method for producing solid formulations with improved dissolution by annealing with an adjuvant | October 2017 | September 2021 | Abandon | 47 | 4 | 1 | No | No |
| 15727772 | COMPOSITIONS FOR TOPICAL TREATMENT OF MICROBIAL INFECTIONS | October 2017 | September 2024 | Allow | 60 | 10 | 0 | Yes | No |
| 15062499 | ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDS | March 2016 | March 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 14883720 | INHIBITORS OF BETA-SECRETASE | October 2015 | November 2018 | Allow | 37 | 2 | 1 | Yes | No |
| 14792375 | Na/K-ATPase Ligand and Uses Thereof in Wound Healing | July 2015 | September 2016 | Allow | 14 | 1 | 0 | Yes | No |
| 14734999 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | June 2015 | May 2018 | Allow | 35 | 3 | 0 | Yes | Yes |
| 14342889 | PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOF | March 2014 | June 2020 | Abandon | 60 | 8 | 0 | Yes | Yes |
| 14010354 | 2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders | August 2013 | May 2015 | Allow | 21 | 1 | 0 | No | No |
| 13965499 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | August 2013 | June 2015 | Allow | 22 | 3 | 0 | Yes | No |
| 13942245 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM | July 2013 | June 2015 | Allow | 23 | 3 | 0 | Yes | No |
| 13986573 | Method for treament of neurologic dysfunction | May 2013 | February 2016 | Allow | 60 | 2 | 0 | No | No |
| 13642907 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | November 2012 | September 2015 | Allow | 34 | 3 | 0 | Yes | No |
| 13592235 | Stable Bortezomib Formulations | August 2012 | June 2015 | Allow | 34 | 3 | 1 | Yes | No |
| 13592228 | Stable Bortezomib Formulations | August 2012 | April 2015 | Allow | 31 | 3 | 0 | Yes | No |
| 13415067 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | March 2012 | June 2012 | Allow | 3 | 0 | 0 | Yes | No |
| 13327226 | METHODS FOR IMPROVING COGNITIVE FUNCTION | December 2011 | November 2014 | Allow | 35 | 2 | 1 | Yes | Yes |
| 13123496 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | May 2011 | March 2018 | Allow | 60 | 4 | 1 | No | Yes |
| 13072568 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | March 2011 | September 2013 | Allow | 29 | 1 | 1 | Yes | No |
| 13051102 | STABLE BORTEZOMIB FORMULATIONS | March 2011 | February 2015 | Allow | 47 | 4 | 1 | Yes | Yes |
| 13031393 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | February 2011 | October 2014 | Allow | 44 | 2 | 1 | No | No |
| 12919416 | CHEMICAL COMPOUNDS HAVING ANTIVIRAL ACTIVITY AGAINST DENGUE VIRUS AND OTHER FLAVIVIRUSES | November 2010 | January 2014 | Allow | 41 | 2 | 1 | Yes | No |
| 12600637 | NOVEL COMPOSITIONS COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR AND THEIR USE IN METHODS OF TREATMENT | October 2010 | November 2012 | Allow | 36 | 2 | 1 | Yes | No |
| 12063996 | Vector Delivery-Based Microbicides | September 2010 | August 2015 | Allow | 60 | 4 | 1 | Yes | No |
| 12856414 | TIVOZANIB AND TEMSIROLIMUS IN COMBINATION | August 2010 | May 2011 | Allow | 9 | 2 | 0 | Yes | No |
| 12832558 | Substituted Phenyl(oxy/thio)alkanol Derivatives | July 2010 | August 2015 | Allow | 60 | 4 | 1 | Yes | No |
| 12813721 | Materials and Methods for Inhibiting Mamalian S-Nitrosoglutathione Reductase | June 2010 | January 2015 | Allow | 56 | 2 | 1 | Yes | No |
| 12682064 | METHODS OF TREATMENT OF OPIOID TOLERANCE, PHYSICAL DEPENDENCE, PAIN AND ADDICTION WITH INHIBITORS OF CERTAIN GROWTH FACTOR RECEPTORS | April 2010 | April 2013 | Allow | 36 | 3 | 1 | Yes | No |
| 12680484 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | March 2010 | February 2014 | Allow | 46 | 2 | 1 | Yes | Yes |
| 12698116 | PHARMACEUTICAL CREAMS WITH REFINED OLEIC ACID | February 2010 | January 2011 | Allow | 11 | 3 | 0 | Yes | No |
| 12698039 | METHOD OF TREATING A MUCOSAL AND/OR DERMAL ASSOCIATED CONDITION | February 2010 | January 2011 | Allow | 12 | 3 | 0 | Yes | No |
| 12698011 | METHOD OF TREATING A DERMAL AND/OR MUCOSAL ASSOCIATED CONDITION | February 2010 | January 2011 | Allow | 12 | 3 | 0 | Yes | No |
| 12698096 | PHARMACEUTICAL CREAMS WITH REDUCED IMIQUIMOD IMPURITIES | February 2010 | December 2010 | Allow | 11 | 3 | 0 | Yes | No |
| 12697415 | METHOD OF INDUCING INTERFERON BIOSYNTHESIS | February 2010 | January 2011 | Allow | 13 | 3 | 0 | Yes | No |
| 12698113 | REDUCTION OF IMIQUIMOD IMPURITIES IN PHARMACEUTICAL CREAMS | February 2010 | January 2011 | Allow | 11 | 3 | 0 | Yes | No |
| 12697296 | METHOD OF INDUCING CYTOKINE BIOSYNTHESIS | January 2010 | January 2011 | Allow | 12 | 3 | 0 | Yes | No |
| 12657052 | METHOD FOR TREATMENT OF NEUROLOGIC DYSFUNCTION | January 2010 | December 2012 | Allow | 35 | 1 | 1 | Yes | No |
| 12645094 | SMALL MOLECULE INHIBITION OF INTRACELLULAR TRANSPORT | December 2009 | April 2012 | Allow | 28 | 0 | 1 | No | No |
| 12437679 | STABLE PHARMACEUTICAL FORMULATIONS | May 2009 | February 2012 | Allow | 33 | 2 | 1 | No | Yes |
| 11887502 | PHOSPHONO-PENT-2-EN-1-YL NUCLEOSIDES AND ANALOGS | January 2009 | March 2012 | Allow | 53 | 0 | 1 | No | No |
| 12158918 | Cleansing Composition | October 2008 | September 2015 | Allow | 60 | 4 | 1 | Yes | No |
| 12201226 | NON-AQUEOUS PHARMACEUTICAL COMPOSITION | August 2008 | October 2014 | Allow | 60 | 3 | 1 | Yes | No |
| 12094255 | ORGANIC SULFUR COMPOUNDS AND USE THEREOF | May 2008 | May 2011 | Allow | 36 | 1 | 1 | No | No |
| 11557455 | TREATMENT OF LENGTH DEPENDENT NEUROPATHY | November 2006 | May 2011 | Allow | 55 | 2 | 1 | Yes | Yes |
| 11542010 | TREATMENT FOR PARKINSON'S DISEASE-COMBINATION HIGH DOSE SEROTONERGIC SYNAPTIC REUPTAKE INHIBITOR WITH PHOSPHODIESTERASE INHIBITOR | October 2006 | May 2014 | Allow | 60 | 7 | 0 | Yes | Yes |
| 11535001 | METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS | September 2006 | September 2010 | Allow | 48 | 1 | 1 | Yes | No |
| 11457063 | "METHODS AND PRODUCTS FOR TREATMENT OF DISEASES" | July 2006 | January 2014 | Allow | 60 | 2 | 1 | No | Yes |
| 11412353 | METHODS OF AND COMPOSITIONS FOR REDUCING NEURONAL CELL DEATH | April 2006 | December 2010 | Allow | 56 | 2 | 1 | No | No |
| 11369638 | TOPICAL ANTIPSYCHOTIC COMPOSITION | March 2006 | August 2010 | Allow | 53 | 2 | 1 | Yes | No |
| 11026198 | METHODS FOR IMPROVING THE AESTHETIC APPEARANCE OF SKIN | December 2004 | August 2010 | Allow | 60 | 2 | 1 | No | Yes |
| 10992878 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | November 2004 | November 2009 | Allow | 60 | 1 | 1 | Yes | No |
| 10988337 | PHARMACOLOGICAL USES OF AZETIDINE DERIVATIVES | November 2004 | February 2010 | Allow | 60 | 2 | 1 | Yes | No |
| 10823365 | TOPICAL ANESTHETIC/OPIOID FORMULATIONS AND USES THEREOF | April 2004 | June 2010 | Allow | 60 | 6 | 2 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCMILLIAN, KARA RENITA.
With a 10.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MCMILLIAN, KARA RENITA works in Art Unit 1623 and has examined 95 patent applications in our dataset. With an allowance rate of 73.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 36 months.
Examiner MCMILLIAN, KARA RENITA's allowance rate of 73.7% places them in the 30% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MCMILLIAN, KARA RENITA receive 2.71 office actions before reaching final disposition. This places the examiner in the 90% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MCMILLIAN, KARA RENITA is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +29.6% benefit to allowance rate for applications examined by MCMILLIAN, KARA RENITA. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 20.6% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.7% of cases where such amendments are filed. This entry rate is in the 50% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 56.5% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 69.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 33.3% are granted (fully or in part). This grant rate is in the 26% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 4.2% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.